ArticleJournal of gastric cancer2026
OLGA and OLGIM Stages for Predicting Metachronous Gastric Neoplasm After Endoscopic Submucosal Dissection in Patients With Early Gastric Cancer Without a Current
Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe operative link on gastritis assessment (OLGA) and operative link on gastritis assessment based on intestinal metaplasia (OLGIM) are established tools for stratifying the risk of gastric neoplasm development. This study evaluated whether OLGA and OLGIM staging can predict metachronous gastric neoplasms (adenoma or cancer) after endoscopic submucosal dissection (ESD) in patients with early gastric cancer (EGC) without current MATERIALS AND
methodsThis retrospective cohort study enrolled 494 patients with EGC without current
resultsOf the included patients, 55.4% (250/451) and 55.9% (276/494) were classified as high risk according to OLGA and OLGIM staging, respectively. During a median follow-up of 6.8 years, the incidence of metachronous gastric neoplasm was 26.6 cases per 1,000 person-years. According to OLGA staging, the high-risk group had a significantly higher incidence of metachronous neoplasms than the low-risk group (33.3 vs. 17.8 cases per 1,000 person-years, log-rank test P=0.012). Similarly, according to OLGIM staging, the high-risk group demonstrated a significantly higher incidence than the low-risk group (35.2 vs. 16.6 cases per 1,000 person-years, P=0.002).
conclusionsIn patients with EGC without current
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.